Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis

Li, Ji; Wang, Ping; Xu, Yang

doi:10.1371/journal.pone.0179536

Cited by 38 publications

(35 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the first publication, Li et al found no correlation between PD-L1 expression and OS/DFS in patients with head and neck cancer. 19 In their subgroup analysis, the authors reported that PD-L1 expression was not associated with OS in NPC, in accordance with our findings, but found that positive PD-L1 expression was associated with poor DFS in patients with NPC. Of note, both of these results were based upon a fixed statistical model due to low heterogeneity.…”

Section: Prognostic Role Of Pd-l1 In Npcsupporting

confidence: 91%

The Prognostic Role of Programmed Death‐Ligand 1 in Nasopharyngeal Carcinoma

et al. 2020

View full text Add to dashboard Cite

Objectives: Programmed death-ligand 1 (PD-L1) is an immune checkpoint protein that may be a useful prognostic biomarker in nasopharyngeal cancer (NPC). The purpose of this systematic review and meta-analysis was to investigate the relationship between PD-L1 expression and survival in NPC. Methods: PubMed, Cochrane, Embase, Scopus, and Web of Science were searched from inception to present. A predefined inclusion and exclusion criteria were used to select articles. Hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled for overall survival (OS), disease-free survival (DFS), and disease metastasis-free survival (DMFS).

show abstract

Section: Prognostic Role Of Pd-l1 In Npcsupporting

confidence: 91%

The Prognostic Role of Programmed Death‐Ligand 1 in Nasopharyngeal Carcinoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…On the contrary, others report a negative prognostic impact of PD-L1 expression in ovarian cancer [ 39 , 40 ] and breast cancer [ 41 ]. In a review and meta-analysis of 17 studies using data of 2869 head and neck cancer (HNC) patients, authors found that there was no significant association between the expression of PD-L1 on survival in HNC patients [ 42 ]. Additionally, similar analysis of reports with NSCLC patients also did not show a significant association with PD-L1 expression and survival [ 43 ].…”

Section: Discussionmentioning

confidence: 99%

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer

et al. 2018

View full text Add to dashboard Cite

BackgroundOvarian cancer is the major cause of death among gynecologic cancers with 75% of patients diagnosed with advanced disease, and only 20% of these patients having a survival duration of five years. Treatments blocking immune checkpoint molecules, programmed cell death (PD-1) or its ligand PD-ligand- I (PD-L1) have produced a beneficial and prolonged effect in a subgroup of these patients. However, there is debate in the literature concerning the prognostic value of the expression of these molecules in tumors, with immunotherapy responsiveness, and survival.We evaluated the immune landscape of the ovarian tumor microenvironment of patients, by measuring the impact of the expression of tumor PD-1, PD-L1 and infiltrating lymphocytes on stage and grade of tumors and survival, in a cohort of 55 patients with gynecologic malignancies. Most patients under study were diagnosed with advanced disease ovarian cancer.ResultsOur studies revealed that a low density of PD-1 and of PD-L1 expressing cells in tumor tissue were significantly associated with advanced disease (P = 0.028 and P = 0.033, respectively). Moreover, PD-L1 was expressed significantly more often in high grade tumors (41.5%) than in low grade tumors of patients (7.7%) (P = 0.040). The presence of CD3 or of FoxP3 infiltrating cells with PD-L1 in patient tumors did not impact the significance of the association of PD-L1 with high grade tumors (P = 0.040), and our analyses did not show an association between the presence of PD-1 or PD-L1 and survival.ConclusionsWe conclude that a subgroup of advanced disease ovarian cancer patients with high grade tumors, expressing PD-L1, may be prime candidates for immunotherapy targeting PD-1 signaling.Electronic supplementary materialThe online version of this article (10.1186/s13048-018-0414-z) contains supplementary material, which is available to authorized users.

show abstract

“…[ 36 – 40 ] However, inconsistent results have been reported in esophageal squamous cell cancer, and head and neck cancer, with no association between PD-L1 expression and survival. [ 41 , 42 ]…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma

et al. 2018

View full text Add to dashboard Cite

Background:Programmed cell death ligand 1 (PD-L1) overexpression has been reported to be associated with poor prognosis in several human cancers. However, studies on the prognostic value of PD-L1 expression in ovarian carcinoma (OC) remain controversial. This meta-analysis aimed to evaluate comprehensively the prognostic value of PD-L1 in OC.Methods:Electronic databases, including PubMed, EMBASE, and the Cochrane Library, were searched up until March 28, 2018. Hazard ratio (HR), along with 95% confidence interval (CI), was used to analyze the included outcomes.Results:A total of 10 studies with 1179 OC patients were included in this meta-analysis. There was no significant correlation between PD-L1 expression and overall survival (OS) (HR 1.23, 95% CI 0.85–1.79) and progression-free survival (PFS) (HR 0.88, 95% CI 0.52–1.47) of OC patients. However, the subgroup analysis suggested that positive PD-L1 expression was significantly associated with poor OS (HR 1.66, 95% CI 1.08–2.55) and PFS (HR 2.17, 95% CI 1.31–3.61) among OC patients from Asian countries. Increased PD-L1 expression was also a favorable factor for OS (HR 0.73, 95% CI 0.53–0.99) and PFS (HR 0.58, 95% CI 0.45–0.75) in OC patients from non-Asian regions. No evidence of publication bias was detected by the Egger linear regression test and Begg funnel plot. Sensitivity analyses suggested that the results of this meta-analysis were robust.Conclusions:The results indicated that PD-L1 expression may be a negative predictor for prognosis of OC patients from Asian countries, and a good predictor for favorable prognosis of OC patients from non-Asian countries. PD-L1 expression has potential to be a prognostic biomarker to guide clinicians for the selection of individuals who may get clinical benefit from anti-PD-1/PD-L1 immunotherapy. Prospective clinical studies are needed to support these findings.

show abstract

Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis

Cited by 38 publications

References 51 publications

The Prognostic Role of Programmed Death‐Ligand 1 in Nasopharyngeal Carcinoma

The Prognostic Role of Programmed Death‐Ligand 1 in Nasopharyngeal Carcinoma

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer

Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma

Contact Info

Product

Resources

About